02:22 AM EDT, 05/14/2026 (MT Newswires) -- British drugmaker AstraZeneca (AZN.L, AZN.ST) said Thursday that the interim analysis of a late-stage study of its combination therapy for muscle-invasive bladder cancer showed improvements in event-free survival and overall survival.

In the Volga phase III trial, perioperative treatment with Imfinzi, or durvalumab, in combination with neoadjuvant enfortumab vedotin, improved event-free survival and overall survival in patients, compared with standard of care.

On the other hand, a significant improvement in event-free survival was noted in perioperative treatment with Imfinzi plus Imjudo, or tremelimumab, in combination with neoadjuvant enfortumab vedotin. However, the overall survival data were not statistically significant and will be formally reassessed at a subsequent analysis, the company noted.

Imfinzi's safety profile, with or without combination therapy, was consistent with the known safety profiles of the individual medicines, with no new safety signals identified.